As biologics and novel modalities become increasingly sophisticated, understanding molecular structure under controlled conditions tells only part ...
For emerging biopharma companies, speed, quality and scalability cannot be treated as separate priorities. As products progress t...
Scientific breakthroughs are advancing rapidly across complex biologics, cell and gene therapies, radiopharmaceuticals and ADCs, but translating th...
As cell and gene therapies progress towards broader commercialisation, scientific innovation alone is no longer enough. The next generation of ther...
As advanced therapies move from development towards commercial scale, quality is becoming far more than a regulatory checkpoint. It is increasingly...
Early detection remains one of the biggest challenges in cancer care, particularly for ovarian cancer, where symptoms can be difficult to r...
The development of cannabinoid and psychedelic medicines is entering a more evidence-driven phase, with clinical validation, safety, regulatory a...
As AI and digital technologies increasingly influence pharmaceutical development, CDMOs are taking on a broader role in helping sponsors im...
As breast imaging continues to evolve toward more quantitative and patient-centred approaches, QT Imaging is developing a three-dimensional ultraso...
Pfizer Inc. (NYSE: PFE) and Valneva SE (Nasdaq: VALN; Euronext Paris: VLA) announced that the European Medicines Agency (EMA) has validated the Mar...
Drug development is inherently uncertain, with scientific discoveries, manufacturing challenges, regulatory expectations and commercial priorities ...
Bone Biologics is developing a targeted approach to bone regeneration through its proprietary NELL-1 platform, designed to address the li...
The recent Bundibugyo Ebola virus outbreak underscored the limitations of relying solely on highly targeted diagnostics, highlighting the need for more ada...
Enterprise-grade Signals software with guided onboarding positioned specifically for early-stage biotechs Science-first setup with ready-to-use...
© 2026 Biopharma Boardroom. All Rights Reserved.
